Pluri Inc. PLUR PHARMA

Q: What is the current share price of Pluri Inc. (PLUR)?

As of 2026-09-19 21:16 PDT, Pluri Inc. (PLUR) trades at $1.27 on NasdaqCM. Its 52-week range is $1.27 to $5.68.

Q: What is the market capitalisation of PLUR?

Pluri Inc. (PLUR) has a market capitalisation of $15.68M on NasdaqCM.

Q: What is the P/E ratio of PLUR?

PLUR trades at a trailing price-to-earnings (P/E) ratio of -0.52. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -0.51.

Q: Is PLUR a good stock to buy?

This page provides a data-driven analysis of Pluri Inc. (PLUR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · Israel

https://www.pluri-biotech.com

Company Profile ↓

$1.27

-73.87% 1Y

Mkt Cap$15.68M

P/E-0.52

P/B-0.51

52W High$5.68

52W Low$1.27

Book Value$-2.13

EPS (TTM)$-2.44

Company Overview

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform. Its product candidates include PLX-PAD, which is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. The company also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. It operates in the field of regenerative medicine, food tech, immunotherapy, as well as contract development and manufacturing organization (CDMO) services for pharmaceutical and biotechnology companies under the PluriCDMO division, and AgTech. It has a collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Recent Developments

Jun 2025 Revenue of $1.34M (+309.8% YoY); net profit $-22.58M.
Trailing 12 Months Year-on-year growth — revenue -15.8%.
5-Year Trend Long-term compounding — revenue CAGR 5.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	5.83%
1 Year:	-15.80%

Stock Price Performance

1 Year:	-73.87%
6 Months:	-62.31%
3 Months:	-45.02%
1 Month:	-30.22%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 0% of range

$1.27 $5.68

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)30.22 · Neutral

Price Performance

1M-30.22%

3M-45.02%

6M-62.31%

1Y-73.87%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

Trading 77.6% below its 52-week high.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-0.52

Industry PE

24.83

Forward P/E

-0.67

PEG Ratio

Book Value

$-2.13

Price to Book

-0.51

P/S

13.12

EV/EBITDA

-1.89

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

5.83%

Profit 5Y

Revenue (YoY)

-15.80%

Earnings (YoY)

Profitability & Returns

ROCE

ROE

ROA

-49.04%

Profit Margin

0.00%

Op Margin

Gross Margin

44.59%

EPS (Latest Qtr)

$-0.55

EPS (TTM)

$-2.44

Balance Sheet & Liquidity

Debt/Equity

Quick Ratio

0.24

Current Ratio

0.27

Debt

$34.91M

Total Assets

$26.06M

Current Assets

$10.46M

Working Capital

$-10.23M

Ownership

Promoter Holding

42.52%

Chg in Prom Hold

-5.72%

FII / Inst Holding

20.68%

Chg in FII Hold

8.14%

Financial Snapshot

Enterprise Value

$15.68M

Total Revenue (TTM)

$1.02M

EBITDA

$-24.43M

Free Cash Flow

$-12.10M

Operating Cash Flow

$-19.59M

Shares Outstanding

12.34M

Gross Margin

44.59%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	PLUR Pluri Inc. PHARMA	1.27	-0.52	$15.68M	0.00%	-	-	5.83%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Sep 2013	Dec 2013	Mar 2014	Sep 2014	Dec 2014	Mar 2015	Sep 2015	Dec 2015	Mar 2016	Sep 2016	Dec 2016	Mar 2017	Sep 2017	Dec 2017	Mar 2018	Sep 2018	Dec 2018	Mar 2019	Sep 2019	Dec 2019	Mar 2020	Sep 2020	Dec 2020	Mar 2021	Sep 2021	Dec 2021	Mar 2022	Sep 2022	Dec 2022	Mar 2023	Sep 2023	Dec 2023	Mar 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	95.00K	95.00K	95.00K	95.00K	95.00K	95.00K	95.00K	2.75M	-	-	-	-	-	50.00K	-	4.00K	50.00K	-	-	23.00K	-	-	-	-	-	-	234.00K	87.00K	2.00K	87.00K	54.00K	105.00K	71.00K	326.00K	-	427.00K	398.00K	316.00K	198.00K	167.00K
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	291.00K	191.00K	201.00K	112.00K	111.00K
Gross Profit	92.00K	92.00K	92.00K	92.00K	91.00K	92.00K	92.00K	2.65M	-	-	-	-	-	48.00K	-	4.00K	48.00K	-	-	22.00K	-	-	-	-	-	-	-	-	-	-	54.00K	105.00K	71.00K	200.00K	-	136.00K	207.00K	115.00K	86.00K	56.00K
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.54M	6.83M	6.46M	6.59M	6.59M
Operating Income	-4.86M	-6.99M	-9.29M	-5.62M	-6.30M	-7.53M	-5.52M	-4.23M	-7.39M	-6.56M	-6.65M	-8.22M	-7.44M	-8.47M	-9.05M	-8.97M	-8.33M	-10.30M	-7.20M	-6.37M	-7.40M	-8.74M	-13.07M	-14.22M	-11.44M	-10.79M	-10.47M	-6.92M	-6.68M	-7.10M	-5.38M	-5.21M	-5.53M	-5.20M	-	-5.40M	-6.62M	-6.35M	-6.51M	-6.54M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-6.05M	-7.43M	-5.78M	-6.52M	-5.82M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	212.00K	233.00K	229.00K	231.00K	237.00K
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-6.33M	-7.77M	-6.14M	-6.88M	-6.18M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-8.00K	-8.00K	-8.00K
Net Income	-4.75M	-6.71M	-9.28M	-5.91M	-6.25M	-7.23M	-5.88M	-3.96M	-7.20M	-6.32M	-6.61M	-7.86M	-7.38M	-8.23M	-1.53M	-8.79M	-8.68M	-10.08M	-7.14M	-6.37M	-7.51M	-8.49M	-12.55M	-14.25M	-11.43M	-10.94M	-9.87M	-6.12M	-8.12M	-7.62M	-4.96M	-4.91M	-5.29M	-5.88M	-	-6.15M	-7.60M	-5.85M	-6.54M	-5.55M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.36	-0.34	-0.31	-0.19	-0.24	-1.52	-0.96	-0.96	-1.01	-1.08	-0.53	-0.94	-	-0.65	-0.71	-0.55
R&D Expense	5.50M	6.11M	6.88M	5.74M	5.38M	6.18M	5.06M	5.57M	5.80M	6.03M	5.48M	6.58M	5.19M	6.26M	7.48M	7.76M	7.43M	8.42M	5.83M	5.57M	5.74M	6.20M	8.00M	7.82M	6.39M	6.54M	6.27M	4.50M	3.79M	4.17M	2.99M	2.96M	3.09M	2.89M	2.92M	3.04M	-	3.93M	3.83M	3.96M

Profit & Loss (Annual)

Figures in USD.

Metric	Jun 2010	Jun 2011	Jun 2012	Jun 2013	Jun 2014	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Revenue	-	-	716.00K	679.00K	379.00K	379.00K	2.85M	-	50.00K	54.00K	23.00K	-	234.00K	287.00K	326.00K	1.34M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	0	9.00K	4.00K	682.00K
Gross Profit	-	-	695.00K	659.00K	368.00K	366.00K	2.75M	-	48.00K	52.00K	23.00K	-	234.00K	278.00K	322.00K	654.00K
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	41.83M	27.52M	22.48M	22.83M
Operating Income	-7.44M	-11.11M	-15.03M	-22.22M	-27.85M	-25.27M	-23.32M	-28.02M	-33.73M	-35.53M	-29.48M	-50.62M	-41.59M	-27.25M	-22.16M	-22.18M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-39.43M	-27.68M	-20.23M	-22.07M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	887.00K	843.00K	866.00K	873.00K
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-41.37M	-28.89M	-21.34M	-23.25M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-5.00K
Net Income	-7.45M	-10.85M	-14.79M	-21.16M	-26.93M	-24.68M	-23.25M	-27.81M	-26.13M	-35.31M	-29.15M	-49.87M	-41.24M	-28.32M	-20.89M	-22.58M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-1.77	-10.24	-6.24	-3.99	-3.56
R&D Expense	6.12M	8.31M	12.69M	19.91M	24.94M	23.42M	22.86M	24.00M	26.37M	29.88M	23.10M	30.53M	24.61M	15.74M	12.45M	12.85M

Balance Sheet (Annual)

Figures in USD.

Metric	Jun 2009	Jun 2010	Jun 2011	Jun 2012	Jun 2013	Jun 2014	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Total Assets	-	-	46.02M	47.42M	68.32M	74.02M	68.16M	45.94M	37.53M	38.96M	31.31M	65.53M	93.54M	68.06M	50.80M	39.53M	38.68M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	57.75M	41.41M	31.11M	22.09M
Cash & Equivalents	2.34M	1.58M	42.83M	9.39M	9.01M	4.49M	22.63M	6.22M	4.71M	8.82M	4.11M	8.27M	31.24M	9.77M	5.36M	6.78M	5.89M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	955.00K	360.00K	501.00K	424.00K
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	35.88M	35.50M	34.11M	39.55M
Current Liabilities	-	-	2.02M	5.52M	5.92M	7.40M	6.18M	5.78M	5.41M	8.55M	8.16M	7.99M	11.52M	6.83M	5.62M	4.45M	32.33M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	21.68M	23.53M	24.03M	-
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	28.80M	29.91M	29.61M	34.05M
Total Equity	3.39M	3.98M	43.42M	37.74M	57.47M	62.12M	58.14M	38.16M	30.25M	28.51M	21.82M	56.10M	57.15M	30.04M	13.36M	96.00K	-6.84M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	4.06M	5.16M	5.41M	7.89M

Cash Flows (Annual)

Figures in USD.

Metric	Jun 2010	Jun 2011	Jun 2012	Jun 2013	Jun 2014	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Operating Cash Flow	-5.41M	-5.75M	-3.27M	-16.89M	-	-20.61M	-18.52M	-21.61M	-21.38M	-29.45M	-26.37M	-30.91M	-36.50M	-22.86M	-18.02M	-18.21M
Investing Cash Flow	-1.30M	-36.00K	-30.80M	-19.80M	-	21.54M	1.31M	4.36M	5.68M	1.17M	-30.46M	-7.26M	11.78M	9.70M	10.58M	8.03M
Financing Cash Flow	5.95M	47.04M	632.00K	36.30M	-	17.20M	807.00K	15.80M	19.92M	23.58M	60.87M	61.40M	7.50M	8.02M	8.84M	9.53M
Capital Expenditure	-389.00K	-962.00K	-1.48M	-4.31M	-1.57M	-831.00K	-1.75M	-378.00K	-342.00K	-239.00K	-270.00K	-373.00K	-280.00K	-262.00K	-323.00K	-1.62M
Free Cash Flow	-5.80M	-6.72M	-4.75M	-21.20M	-	-21.44M	-20.27M	-21.99M	-21.72M	-29.69M	-26.64M	-31.28M	-36.78M	-23.12M	-18.34M	-19.83M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-17.22M	-5.13M	1.40M	-652.00K

Ratios (Annual)

Figures in %.

Metric	Jun 2010	Jun 2011	Jun 2012	Jun 2013	Jun 2014	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Gross Margin %	-	-	97.1%	97.1%	97.1%	96.6%	96.5%	-	96.0%	96.3%	100.0%	-	100.0%	96.9%	98.8%	49.0%
Operating Margin %	-	-	-2,099.3%	-3,272.9%	-7,348.3%	-6,666.8%	-819.1%	-	-67,462.0%	-65,800.0%	-128,156.5%	-	-17,774.8%	-9,493.4%	-6,796.9%	-1,659.9%
Net Margin %	-	-	-2,066.2%	-3,115.6%	-7,106.1%	-6,511.1%	-816.5%	-	-52,252.0%	-65,383.3%	-126,747.8%	-	-17,624.8%	-9,867.9%	-6,407.4%	-1,690.3%
ROE %	-187.2%	-25.0%	-39.2%	-36.8%	-43.4%	-42.4%	-60.9%	-91.9%	-91.6%	-161.8%	-52.0%	-87.3%	-137.3%	-212.1%	-21,758.3%	330.1%
ROCE %	-	-25.3%	-35.9%	-35.6%	-41.8%	-40.8%	-58.1%	-87.2%	-110.9%	-153.5%	-51.2%	-61.7%	-67.9%	-60.3%	-63.2%	-349.0%

Shareholding Pattern

Insiders

42.52%

Institutions

20.68%

Public Float

35.98%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Renaissance Technologies, LLC	0.15%	18.32K	$19.79K
2	Eversource Wealth Advisors, Llc	0.02%	2.00K	$2.16K
3	Morgan Stanley	0.02%	2.98K	$3.22K
4	UBS Group AG	0.02%	1.92K	$2.07K
5	SBI Securities Co., Ltd.	-	97	$104
6	Sima Wealth Partners, LLC	-	350	$378
7	Citigroup Inc.	-	191	$206
8	JPMORGAN CHASE & CO	-	125	$135
9	Wells Fargo & Company	-	185	$199
10	Royal Bank of Canada	-	125	$135

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for PLUR

Google News Fri, 04 Sep 2026

Pluri (PLUR) turns to private warrants for funding - Stock Titan

<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxQejFYb29jdW9nSldBT3dfQnI3THJGVXhmcklkSjFnUU5fNGFCaThsTlp3NHJEdDJwd202SDRjeENHTFBwN1Mxc0VvYXFMZHR1Nm9xT3hYcG9CYV9ibENwd2NHZ0pwVFRFWGt2b00yU0JZeTBTY2ZFaWVvYWxia1J2dGliaHBBbkN4X1NoSA…

Google News Wed, 02 Sep 2026

Insiders' US$14.6m Investments In Red Following Pluri's US$2.2m Dip In Market Value - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxQOG5fTVVDSFVBcmhpZWhGZzJmZ0xHa2lMbFdFUG4zazhtMDh5OTMxVWd4OEU4b1dSYWZORXNTMjVud2d4Um1wUVRFblJ1TE96SWt2TmlnY2JnN2F1US0teV9idi1WZ0FqbWNaV3Bsb0l1eTVTeUx6aGo2UlZBQWpxM2ZJTjZ6OEtHNGtDSF…

Google News Fri, 04 Sep 2026

Pluri Inc. (PLUR) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxPbTJWYmM2bVM5NXZ0OW9CYTVvUUxWSHBVQVVjRlZvbzRZU3p5WjBMNVpBRXJrc2Z0ZUg5ZW1kUDc1U0NXSW5vSmpHU2JObVJPMEg2NzViX0M5MFJPV3NlY3JwYlF5dWxRYlRSd3c0bl8yR1FsaTU2SGpHWHVITmRSb2U2b2Q?oc=5" targ…

Google News hu, 27 Aug 2026

Pluri plans a $3.3 million share sale and rights to buy more shares - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxQVFRlQTRFamluZWhVNk5wS28wR2tmYmdsR3FSbjBrNVBZeWRwc041MkQ2eTVMQlVNUGZZWG43TU9FRVE5ZEVQQ2t6MVZPakdEbXVLUlptd0RyTER2RjRDRnlwdE1EaXF0a2ZVcXltTnUzV2dncExmNHRKTU1TR0NEU2lsT2YyNlc1Zl8wa0…

Google News Sat, 30 May 2026

Pluri Inc. (PLUR): One of the Premier Lab-Grown Meat Stocks to Invest In - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxQaF9zRXNRSEhJOXJ0RnBhY2tZQ1Rad0xlcFppd2ZxbTQzR2VMaHdudVpobEhVNC1QZHRuSEhnaVVES0dzOUtYQlU0NUNMZnFMRGMybnNEQ0xuZmpmWHM4OHRwbEVuN0tCdGJKWkEzNWd5XzRkQ3ZxeXdLQmZIQWFOVXQxWlFEbUNYUjJLX0…

Google News Mon, 24 Aug 2026

Pluri (PLUR) director's 31,569-share grant vests over 3 years - Stock Titan

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxNVWJMMVFFb3ljN2hUd3RzOGdYWnktaDF2WnRxQkVhMWxvR3NxTVp1UTNUajVUc01ZYUNUb0NlSnFlZzVpcHRteEEtMjgtVDQ3d2VnaExsN1hxcTNmOFhaU2MzODBsc2pSRG95M2dvVTlFTl8tSjk5RWh5MnVwN0pQNHEzSFlCSTlJbUZaS1…

PLUR — Frequently Asked Questions

What is the current share price of Pluri Inc. (PLUR)?

As of 2026-09-19 21:16 PDT, Pluri Inc. (PLUR) trades at $1.27 on NasdaqCM. Its 52-week range is $1.27 to $5.68.

What is the market capitalisation of PLUR?

Pluri Inc. (PLUR) has a market capitalisation of $15.68M on NasdaqCM.

What is the P/E ratio of PLUR?

PLUR trades at a trailing price-to-earnings (P/E) ratio of -0.52. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -0.51.

Is PLUR a good stock to buy?

This page provides a data-driven analysis of Pluri Inc. (PLUR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Pluri Inc. PLUR PHARMA

Company Overview

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Pluri (PLUR) turns to private warrants for funding - Stock Titan

Insiders' US$14.6m Investments In Red Following Pluri's US$2.2m Dip In Market Value - simplywall.st

Pluri Inc. (PLUR) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

Pluri plans a $3.3 million share sale and rights to buy more shares - Stock Titan

Pluri Inc. (PLUR): One of the Premier Lab-Grown Meat Stocks to Invest In - finance.yahoo.com

Pluri (PLUR) director's 31,569-share grant vests over 3 years - Stock Titan

PLUR — Frequently Asked Questions

What is the current share price of Pluri Inc. (PLUR)?

What is the market capitalisation of PLUR?

What is the P/E ratio of PLUR?

Is PLUR a good stock to buy?

Explore More